Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or
clopidogrel. However, studies have shown that not all people respond to these medications.
The variance in treatment response may be linked to genetics. This study will examine the
effects of aspirin and clopidogrel in a population whose genes are well known in order to
determine the role that genes play in treatment responses.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institute of General Medical Sciences (NIGMS)